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During last 15 years dopamine has emerged as 
a major regulator of inflammation. All five dopamine 
receptors (DRs, DRD1-DRD5) have been found to be 
expressed in immune cells where they exert a complex 
regulation of immunity [1]. Of note, DRs have been found 
not only in cells of the adaptive immune system, but also 
in cells belonging to the innate immunity, even including 
glial cells. The outcome of the dopamine effect in the 
immune response depends in many factors, including 
differential expression of DRs in the immune cells present 
in the inflamed tissue, the local levels of dopamine and 
the signalling coupled to and the affinity of the different 
DRs involved. An increasing number of studies analysing 
human cells in vitro or using in vivo approaches in 
animal models have been unravelling and deciphering 
the complexity of dopaminergic regulation of immunity. 
Integrating the knowledge acquired by these studies, 
the evidence have indicated that stimulation of low-
affinity DRs, for instance DRD1 and DRD2, are coupled 
to anti-inflammatory mechanisms, thereby dampening 
inflammation [2, 3]. Conversely, signalling triggered by 
high-affinity DRs, including DRD3 and DRD5, have been 
found consistently to promote inflammation [4, 5]. 
It is noteworthy that tissues containing high-levels 
of dopamine in steady-state, such as the nigrostriatal 
pathway or the gut mucosa, undergo a strong decrease 
of dopamine levels during inflammation [1]. This fact 
involves a switch in the stimulation of DRs: low-affinity 
DRs, which display anti-inflammatory properties and are 
stimulated by high dopamine levels under homeostasis, 
are not longer stimulated during inflammatory processes. 
Otherwise, signalling coupled to high-affinity DRs, which 
seems to be dampened by low-affinity DRs stimulation 
under homeostasis, becomes dominant when dopamine 
levels are reduced during inflammation. This idea 
highlight the relevance of high-affinity DRs favouring the 
development and progression of inflammatory disorders 
and makes these receptors key therapeutic targets.
Accordingly, DRD3, which display the highest 
affinity by dopamine, has been strongly involved 
in favouring inflammation in several experimental 
systems. In this regard, genetic and pharmacological 
evidence has indicated that DRD3-signalling constitutes 
a potent regulator of CD4+ T-cell-mediated responses, 
including those implicated in Parkinson’s disease [6] and 
inflammatory colitis [4], two pathologies that involve 
Figure 1: Role of DRD3-signaling in CD4+ T-cells favouring Th1 and Th17 mediated responses in disorders involving 
reduction of dopamine levels in the target tissue, such as Parkinson’s disease and inflammatory bowel diseases.
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a reduction of dopamine levels in the inflamed tissue 
(Figure 1). Mechanistic analyses have revealed that 
DRD3-signalling in CD4+ T-cells induces suppressor 
of cytokine signalling 5 in these cells, thus attenuating 
T-helper 2 (Th2) differentiation and promoting Th1 
responses. Moreover, evidence has also indicated that 
DRD3-signalling favours Th17-immunity under chronic 
inflammatory conditions [4]. According to the pivotal 
role of Th1 and Th17 inflammatory responses in the 
development of Parkinson’s disease, we have recently 
demonstrated the therapeutic potential of DRD3-
antagonism in two different animal models, including 
6-hydroxydopamine-induced and 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine-induced Parkinson’s disease 
[7]. In those studies, DRD3-antagonism not only reduced 
the neurodegenerative and neuroinflammatory process, 
but also attenuated significantly the motor impairment 
associated to the loss of dopaminergic neurons. 
Importantly, the therapeutic effect observed in 
Parkinson’s disease models in our studies [7] was exerted 
by a highly-selective DRD3 antagonist, PG01037, 
displaying the Ki values 0.70, 93.3 and 375 nM for DRD3, 
DRD2 and DRD4 respectively. In apparent controversy 
with our recent findings, pramipexole, a drug described 
as a DRD3-agonist, has been used for the symptomatic 
treatment of Parkinson’s disease. However, the range of 
DRD3-selectivity for this drug is very limited, displaying 
Ki values of 0.5, 3.3, 3.9 and 3.9 nM for DRD3, DRD2S, 
DRD2L and DRD4 respectively. Thereby, it is likely that 
at therapeutic concentrations pramipexole stimulates the 
dominant effects of DRD2-signalling, abolishing DRD3-
mediated effects. 
Interestingly, the therapeutic effect of DRD3-
antagonism seems to be beyond of targeting DRD3 
confined to CD4+ T-cells. Our analyses performed in 
glial cells have suggested that DRD3-deficiency gives 
an anti-inflammatory behaviour to astrocytes, which 
results in attenuated microglial activation in a model of 
Parkinson’s disease [7]. Furthermore, recently we found 
that DRD3-deficiency or DRD3-antagonism in dendritic 
cells results in an exacerbated stimulation of CD8+ T-cell-
mediated immunity, strengthening the immune response 
against tumours [8]. Mechanistic analyses indicated 
that the inhibition of DRD3-signalling in dendritic cells 
promotes an increase in antigen cross-presentation in class 
I MHC molecules to CD8+ T-cells, thereby potentiating the 
development of cytotoxic T-lymphocytes. Thus, emerging 
evidence indicates DRD3 as a key therapeutic target with 
a dual potential: whereas DRD3-inhibtion attenuates 
inflammation in pathologies associated to reduction of 
dopamine levels and CD4+ T-cell-mediated responses 
(Figure 1), blocking DRD3-signalling in dendritic cells 
may improve the outcome of disorders that involve 
insufficient cytotoxic T-lymphocyte-responses, such as 
cancer.
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